HNC-364 is under clinical development by Guangzhou Henovcom Bioscience and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HNC-364’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HNC-364 is under development for the treatment of Parkinson's disease. It is administered through intramuscular route in the form of suspension.
For a complete picture of HNC-364’s drug-specific PTSR and LoA scores, buy the report here.